# | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
---|
Roche's SKYSCRAPER-06 study of tiragolumab plus Tecentriq and chemotherapy did not meet primary endpoints for progression-f...
The medical and pharmaceutical community continues to embrace emerging technologies, beginning with mRNA that rose to fame duri...
Ten of the Dow Jones Industrial Average stocks were up double digit percentage in the first half of 2024. A look at the best an...
Merck secures exclusive global rights to develop and commercialize opevesostat (MK-5684/ODM-208) for hormone-dependent cancers....
The CDC's Advisory Committee on Immunization Practices recommends Merck's Capvaxive for adults 65+ and certain at-risk ...